Apologies, I just checked and I did make an error. I did pull slightly wrong numbers from the model. The relevant value from the detailed analysis I previously posted is:
What if Neuren takes all four through to Approval? This might take 3-5 years. But if Neuren goes it alone, is successful, and then sells, we're now looking at $630-$1002 per share.
So the logic was that if all Ph IIs are positive, then valuing Neuren based upon just 1 drug reaching would be dividing these numbers by 4, giving $157 - $250 (not $130 - $210)
Apologies, I just checked and I did make an error. I did pull...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.72 |
Change
-0.150(0.72%) |
Mkt cap ! $2.648B | |||
| Open | High | Low | Value | Volume |
| $20.96 | $21.28 | $20.61 | $4.984M | 239.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 782 | $20.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.72 | 1021 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |